Watson's Generic Anti-Bleeding Drug Gets FDA Okay

On Thursday, Watson Pharmaceuticals (NYSE: ACT  ) announced that the U.S. Food and Drug Administration has approved its Abbreviated New Drug Application (ANDA) for tranexamic acid tablets, a drug useful in controlling excessive bleeding .

Watson's ANDA product is the generic equivalent of Ferring Pharmaceuticals' Lysteda. Ferring is currently involved in litigation against Watson over the ANDA product, which Ferring says infringes on its patents. Ferring's Lysteda is routinely prescribed for treatment of heavy menstrual bleeding, and IMS Health reports that it generated $25 million in U.S. sales for Ferring in the 12 months ending November 2012.

Shares of Watson closed up 2% on the news at $85.91.

 

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2178240, ~/Articles/ArticleHandler.aspx, 7/25/2014 11:24:34 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement